{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:23:12Z","timestamp":1784568192459,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,23]]},"DOI":"10.7759\/cureus.47526","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T14:43:51Z","timestamp":1698072231000},"source":"Crossref","is-referenced-by-count":8,"title":["Huntington\u2019s Disease: Understanding Its Novel Drugs and Treatments"],"prefix":"10.7759","author":[{"given":"Hitaansh","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa A","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-200397","article-title":"Irritability in Huntington's disease","volume":"9","author":"Karagas NE","year":"2020","unstructured":"Karagas NE, Rocha NP, Stimming EF. Irritability in Huntington's disease. J Huntingtons Dis. 2020, 9:107-13. 10.3233\/JHD-200397","journal-title":"J Huntingtons Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan P","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018, 25:24-34. 10.1111\/ene.13413","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild EJ","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol. 2017, 16:837-47. 10.1016\/S1474-4422(17)30280-6","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28823","article-title":"Juvenile-onset Huntington disease pathophysiology and neurodevelopment: a review","volume":"37","author":"Bakels HS","year":"2022","unstructured":"Bakels HS, Roos RA, van Roon-Mom WM, de Bot ST. Juvenile-onset Huntington disease pathophysiology and neurodevelopment: a review. Mov Disord. 2022, 37:16-24. 10.1002\/mds.28823","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington's disease","volume":"22","author":"Kim A","year":"2021","unstructured":"Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J. New avenues for the treatment of Huntington's disease. Int J Mol Sci. 2021, 22:8363. 10.3390\/ijms22168363","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10010043","article-title":"Therapeutic advances for Huntington's disease","volume":"10","author":"Kumar A","year":"2020","unstructured":"Kumar A, Kumar V, Singh K, Kumar S, Kim YS, Lee YM, Kim JJ. Therapeutic advances for Huntington's disease. Brain Sci. 2020, 10:43. 10.3390\/brainsci10010043","journal-title":"Brain Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2020.01.010","article-title":"Medical, surgical, and genetic treatment of Huntington disease","volume":"38","author":"Stahl CM","year":"2020","unstructured":"Stahl CM, Feigin A. Medical, surgical, and genetic treatment of Huntington disease. Neurol Clin. 2020, 38:367-78. 10.1016\/j.ncl.2020.01.010","journal-title":"Neurol Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01093-3","article-title":"Huntington's disease: new frontiers in therapeutics","volume":"21","author":"Pan L","year":"2021","unstructured":"Pan L, Feigin A. Huntington's disease: new frontiers in therapeutics. Curr Neurol Neurosci Rep. 2021, 21:10. 10.1007\/s11910-021-01093-3","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00695-3","article-title":"Recent advances in the treatment of Huntington's disease: targeting DNA and RNA","volume":"34","author":"Shannon KM","year":"2020","unstructured":"Shannon KM. Recent advances in the treatment of Huntington's disease: targeting DNA and RNA. CNS Drugs. 2020, 34:219-28. 10.1007\/s40263-019-00695-3","journal-title":"CNS Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24845","article-title":"Revisiting cell and gene therapies in Huntington's disease","volume":"99","author":"Beatriz M","year":"2021","unstructured":"Beatriz M, Lopes C, Ribeiro AC, Rego AC. Revisiting cell and gene therapies in Huntington's disease. J Neurosci Res. 2021, 99:1744-62. 10.1002\/jnr.24845","journal-title":"J Neurosci Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez M","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017, 7:a024240. 10.1101\/cshperspect.a024240","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo E","year":"2006","unstructured":"Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006, 67:1268-71. 10.1212\/01.wnl.0000238106.10423.00","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington's disease","volume":"23","author":"Phillips W","year":"2008","unstructured":"Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord. 2008, 23:1491-504. 10.1002\/mds.21971","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283348018","article-title":"Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR","volume":"25","author":"Holl AK","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010, 25:46-50. 10.1097\/YIC.0b013e3283348018","journal-title":"Int Clin Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen M","year":"2000","unstructured":"Chen M, Ona VO, Li M, et al.. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000, 6:797-801. 10.1038\/77528","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009793","article-title":"Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline","volume":"5","author":"Menalled LB","year":"2010","unstructured":"Menalled LB, Patry M, Ragland N, et al.. Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One. 2010, 5:e9793. 10.1371\/journal.pone.0009793","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu A","year":"2002","unstructured":"Dedeoglu A, Kubilus JK, Jeitner TM, et al.. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci. 2002, 22:8942-50. 10.1523\/JNEUROSCI.22-20-08942.2002","journal-title":"J Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2011.11.020","article-title":"Widespread suppression of huntingtin with convection-enhanced delivery of siRNA","volume":"233","author":"Stiles DK","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P, et al.. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol. 2012, 233:463-71. 10.1016\/j.expneurol.2011.11.020","journal-title":"Exp Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu D","year":"2012","unstructured":"Yu D, Pendergraff H, Liu J, et al.. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012, 150:895-908. 10.1016\/j.cell.2012.08.002","journal-title":"Cell"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner J","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, et al.. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014, 81:49-60. 10.1016\/j.neuron.2013.10.061","journal-title":"Neuron"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-010909-095056","article-title":"The discovery of zinc fingers and their applications in gene regulation and genome manipulation","volume":"79","author":"Klug A","year":"2010","unstructured":"Klug A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem. 2010, 79:213-31. 10.1146\/annurev-biochem-010909-095056","journal-title":"Annu Rev Biochem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213476","article-title":"Stem-cell-based therapy: the celestial weapon against neurological disorders","volume":"11","author":"Zayed MA","year":"2022","unstructured":"Zayed MA, Sultan S, Alsaab HO, et al.. Stem-cell-based therapy: the celestial weapon against neurological disorders. Cells. 2022, 11:3476. 10.3390\/cells11213476","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.016","article-title":"Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts","volume":"84","author":"Victor MB","year":"2014","unstructured":"Victor MB, Richner M, Hermanstyne TO, et al.. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron. 2014, 84:311-23. 10.1016\/j.neuron.2014.10.016","journal-title":"Neuron"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington's disease","volume":"60","author":"Alkanli SS","year":"2023","unstructured":"Alkanli SS, Alkanli N, Ay A, Albeniz I. CRISPR\/Cas9 mediated therapeutic approach in Huntington's disease. Mol Neurobiol. 2023, 60:1486-98. 10.1007\/s12035-022-03150-5","journal-title":"Mol Neurobiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj T","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405. 10.1016\/j.tibtech.2013.04.004","journal-title":"Trends Biotechnol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030385","article-title":"Pharmacogenetics in the treatment of Huntington's disease: review and future perspectives","volume":"13","author":"Garc\u00eda-Gonz\u00e1lez X","year":"2023","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cubo E, Sim\u00f3n-Vicente L, et al.. Pharmacogenetics in the treatment of Huntington's disease: review and future perspectives. J Pers Med. 2023, 13:385. 10.3390\/jpm13030385","journal-title":"J Pers Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila SA","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001, 7:249-64. 10.1111\/j.1527-3458.2001.tb00198.x","journal-title":"CNS Drug Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06226-1","article-title":"Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington's disease","volume":"43","author":"Saiz-Rodr\u00edguez M","year":"2022","unstructured":"Saiz-Rodr\u00edguez M, Gil-Polo C, Diez-Fairen M, et al.. Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington's disease. Neurol Sci. 2022, 43:6079-85. 10.1007\/s10072-022-06226-1","journal-title":"Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006, 66:366-72. 10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020099","article-title":"Flavonoids: potential candidates for the treatment of neurodegenerative disorders","volume":"9","author":"Devi S","year":"2021","unstructured":"Devi S, Kumar V, Singh SK, Dubey AK, Kim JJ. Flavonoids: potential candidates for the treatment of neurodegenerative disorders. Biomedicines. 2021, 9:99. 10.3390\/biomedicines9020099","journal-title":"Biomedicines"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3892\/br.2022.1587","article-title":"Recent approaches on Huntington's disease (Review)","volume":"18","author":"Palaiogeorgou AM","year":"2023","unstructured":"Palaiogeorgou AM, Papakonstantinou E, Golfinopoulou R, et al.. Recent approaches on Huntington's disease (Review). Biomed Rep. 2023, 18:5. 10.3892\/br.2022.1587","journal-title":"Biomed Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease","volume":"5","author":"Miniarikova J","year":"2016","unstructured":"Miniarikova J, Zanella I, Huseinovic A, et al.. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease. Mol Ther Nucleic Acids. 2016, 5:e297. 10.1038\/mtna.2016.7","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa139","article-title":"Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1","volume":"29","author":"Mouro Pinto R","year":"2020","unstructured":"Mouro Pinto R, Arning L, Giordano JV, et al.. Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1. Hum Mol Genet. 2020, 29:2551-67. 10.1093\/hmg\/ddaa139","journal-title":"Hum Mol Genet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi SJ","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WM, et al.. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022, 21:645-58. 10.1016\/S1474-4422(22)00121-1","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.05.009","article-title":"Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor","volume":"129","author":"Eddings CR","year":"2019","unstructured":"Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019, 129:118-29. 10.1016\/j.nbd.2019.05.009","journal-title":"Neurobiol Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184798-huntingtons-disease-understanding-its-novel-drugs-and-treatments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:32Z","timestamp":1707509492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184798-huntingtons-disease-understanding-its-novel-drugs-and-treatments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.47526","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,23]]}}}